The acquisition target is common stock, total number of shares acquired is 90,600 shares, total acquisition value is 286,404,500 yen (286,404,500 yen), and the acquisition period is from 2026\/7\/1 to 2026\/7\/31, with the method being market purchases. Cumulative to date is 186,500 shares, total value 603,565,000 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Holden Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4534-20260803-02.pdf","jir_short_summary":"The acquisition target is common stock, total number of shares acquired is 90,600 shares, total acquisition value is 286,404,500 yen (286,404,500 yen), and the acquisition period is from 2026\/7\/1 to 2026\/7\/31, with the method being market purchases. Cumulative to date is 186,500 shares, total value 603,565,000 yen.","jir_summary":"### Transaction overview\nThis notice published today reports the status of share buyback conducted by Holdin Pharmaceutical Co., Ltd. The target shares are the company's common stock, with this acquisition consisting of 90,600 shares for a total of 286,404,500 yen. The acquisition period is from July 1, 2026 to July 31, 2026 on an execution basis, and the method is market purchases on the Tokyo Stock Exchange. Note that at the board meeting held on March 30, 2026, an upper limit of 530,000 shares (1.5% of issued shares) and a total amount of 2,000,000,000 yen were approved; to date, cumulative shares acquired are 186,500 with a total of 603,565,000 yen.\n\n### Impact on shareholders and future outlook\nThe notice states that share buyback is subject to market conditions, and purchases may continue or be halted depending on circumstances. The cumulative acquisition is based on market purchases and is presented as part of shareholder value enhancement and capital policy. Currently, progress relative to the upper limit is limited, but additional buyback plans may be disclosed in the future.","jir_financial_highlights":"Total number of shares acquired: 90,600 shares (No prior information)\nTotal acquisition value: 286,404,500 yen (No prior information)\nAcquisition period: July 1, 2026 to July 31, 2026 (No prior information)\nCumulative shares acquired: 186,500 shares (No prior information)\nCumulative acquisition value: 603,565,000 yen (No prior information)","jir_category":"","jir_hashtags":"#HoldinPharmaceutical, #ShareBuyback, #IR","jir_key_figures":"Total number of shares acquired: 90,600 shares\nTotal acquisition value: 286,404,500 yen\nAcquisition period: July 1, 2026 to July 31, 2026\nCumulative shares acquired: 186,500 shares\nCumulative acquisition value: 603,565,000 yen","jir_meta_title":"Holdin Pharmaceutical \u2013 Notice on Share Buyback Status | July 2026","jir_meta_description":"Details of Holdin Pharmaceutical's share buyback disclosed. Summary of shares acquired, total value, period, method, and cumulative results. Potential changes to future buyback policy depending on market trends.","jir_og_title":"Holdin Pharmaceutical \u2013 Notice on Share Buyback Status | July 2026","jir_og_description":"Holdin Pharmaceutical discloses the status of its share buyback. A concise report of key points such as shares acquired, total value, and period.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-92798","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n